Incyte signals beyond the news: 50+ signals from 4 sources
The latest Incyte signal on this page is from Sep 29, 2026 (Patents): "Incyte was granted a patent for an antibody and T-cell cancer therapy." The busiest sources: Glassdoor (15+), YouTube (15+) and Website changes (14).
Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn
- Signals
- 50+
- Sources
- 4
- Last 90 days
- 23
- Latest
- Sep 29, 2026
Other signals · latest 10
Latest Incyte signals by source
50+ signals for Incyte across 4 sources.
Patents · Patent grant
Incyte was granted a patent for an antibody and T-cell cancer therapy.
In September 2026 Incyte patented a combination treatment for leukemia and lymphoma, pairing CD19-targeting antibodies with gamma delta T-cells.
- Patent title
- Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
- Grant date
- Sep 29, 2026
- Inventors
- Jan Endell, Rainer Boxhammer, Dominik Pretscher
Patents · Patent pace
Incyte Corporation's patent output is slowing: 35 grants in the past year, 2 in the past 30 days.
Over the past year Incyte Corporation received 35 US patent grants; the recent pace (4 in 90 days) is slowing versus its trailing baseline.
- Grants, 12 months
- 35
- Grants, 90 days
- 4
- Grants, 30 days
- 2
- Pace
- Decelerating
Patents · Patent grant
Incyte was granted a patent for A2A and A2B receptor inhibitors.
In September 2026 Incyte patented drug compounds designed to treat cancer and inflammatory, cardiovascular, and neurodegenerative diseases.
- Patent title
- Fused pyrazine derivatives as A2A / A2B inhibitors
- Grant date
- Sep 15, 2026
- Inventors
- Xiaozhao Wang, Peter Niels Carlsen, Gia Hoang, Liangxing Wu
Glassdoor · Benefits praise
Company praised for excellent benefits and stock offerings across two employee reviews
Both a Senior Research Scientist and a Manager Supply Chain highlight the generous benefits package, with one specifically mentioning stock options for all levels.
- Overall rating
- 4.1 of 5
- CEO approval
- 76%
- Reviews read
- 2
- Review window
- Sep 1, 2026 to Sep 3, 2026
Glassdoor · Consistent leadership complaints
Middle management criticized for performance in two recent employee reviews
A Senior Research Scientist reported some middle managers were not very good, while a Manager Supply Chain found no cons. This indicates a potential area for leadership development.
- Overall rating
- 4.1 of 5
- CEO approval
- 76%
- Reviews read
- 2
- Review window
- Sep 1, 2026 to Sep 3, 2026
Website changes · Product update
The portfolio page was updated to reflect the addition of axatilimab 4 CSF-1R 1L chronic GVHD status for mobile GVHD and the addition of axatilimab 4 CSF-1R 1L chronic GVHD | + ruxolitinib status...
The updated program listings include “axatilimab 4 CSF-1R 1L chronic GVHD status for mobile GVHD” and “axatilimab 4 CSF-1R 1L chronic GVHD | + ruxolitinib status for mobile Lymphomas/Leukemias.”
- Page
- /what-we-do/pharmaceutical-portfolio
Website changes · Product expansion
Incyte’s portfolio increased from 17 to 16 clinical compounds and from 20 to 19 approved products, while newly acquired VIVID Phase 3 clinical trials remained listed.
The portfolio changed from “17 Clinical Compounds” and “20 Approved Products” to “16 Clinical Compounds” and “19 Approved Products”; the page continues to identify VGA039 as the VIVID Phase 3 Von Willebrand Disease program.
- Page
- /what-we-do/pharmaceutical-portfolio
Glassdoor · Compensation dissatisfaction
Associate Director reports policies frequently change with little notice
An Associate Director notes that company policies often change without adequate warning, impacting the work environment and creating uncertainty for employees.
- Overall rating
- 4.1 of 5
- CEO approval
- 76%
- Reviews read
- 3
- Review window
- Jul 27, 2026 to Aug 10, 2026
YouTube
CCA Awareness
Incyte promotes awareness for Cholangiocarcinoma through the TestMyCholangio.com initiative.
- Channel
- Matt Reidy
- Views
- 11
- Comments
- 0
- Tags
- Medical Awareness, Cholangiocarcinoma
YouTube
Incyte Corp ($INCY) Q1 2025 Earnings Call
Incyte Corp conducts its Q1 2025 earnings call to discuss financial results and company performance.
- Channel
- Castify Earnings Call
- Views
- 0
- Comments
- 0
- Tags
- Earnings Call, Biopharmaceutical, Financials
Showing 10 of 50+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Incyte with the Signal API
One POST /v1/companies/enrich call with incyte.com returns Incyte signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "incyte.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Same industry
Other signals at related companies
Questions about Incyte other signals
What signals does Autobound track for Incyte besides news and filings?
What are people saying about Incyte online?
What do employees say about working at Incyte?
Has Incyte been granted patents recently?
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .